Navigation Links
Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin

These trials demonstrated that attaching the CTP did not affect the therapeutic activity of FSH or cause a negative immune system response in patients. Modigene has an exclusive license with Washington University for use of the CTP with all proteins except four endocrine proteins, which are licensed to Schering-Plough/Organon.

ABOUT MODIGENE

Modigene Inc. is a publicly-traded biopharmaceutical company utilizing patented technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions in annual global sales. Modigene is currently developing long-acting versions of human growth hormone, erythropoietin, interferon beta, and GLP-1 -- each representing a multi-billion dollar market. For more information on Modigene, please visit www.modigeneinc.com.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. ... SNY ; EURONEXT: SAN) and the life sciences ... to improve care and outcomes for people with type ... in diabetes treatments and devices with Google,s expertise in ... companies will explore how to improve diabetes care by ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... Chicago -based Rush University Medical ... activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor ... motor complete cervical spinal cord injury (SCI). This ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... in the New England ... and JACKSONVILLE, Fla., March 24 A study published ... Medicine suggests that intensive blood glucose (sugar) control ... does not improve outcomes and is associated with an ...
... 24 Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company ... of safety and efficacy data from the first cohort of ... recommended that Anthera,s Phase II clinical trial, known as the ... P hospholipase in A cute C hes ...
Cached Medicine Technology:Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 2Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 3Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 4Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3
(Date:8/31/2015)... ... 2015 , ... When it comes to undergoing a hair transplant, most patients have donor hair ... more volume to the hair on top of the scalp, as well as filling in ... of donor hair on other areas of their head. , What about patients who have ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine Course. ... October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. The ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about ... who are interested in learning more about the procedure beyond the information found on ... Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive ... “Alive Inside” shadows a social worker who advocates for the use of music therapy ... bringing music to residents in health care centers who may have lost a spark ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... Delhi government has decided to construct 36 hospitals.// ... ,"Some of these hi-tech hospitals will be built in ... the chief minister's office. ,"Initially the government had ... but more funds will be made available," the official said. ...
... HIV tests of dental patients in North Quensland. The ... a dentist working// at Bowen and Collinsville hospitals, tested ... testing of patients. Nearly 120 patients have already been ... Jeannette Young expressed that despite some patients getting ...
... during pregnancy do more harm than good according to ... study conducted by researchers revealed that babies born to ... antidepressants have more of a likelihood of having a ... is in contradiction to the belief that treating depressed ...
... the elderly has been blamed on defects in a specific gene ... estimated that about 37% of Britons from ages 61 to 70 ... people are said to have age-related hearing loss. ,The ... changes in the gene, KCNQ4 more frequent among those with age-related ...
... the High-Security Animal Disease Laboratory in Bhopal have finally helped ... against// the deadly H5N1 bird flu virus last month. However, ... to manufacture the vaccine. ,This is because there ... influenza vaccines for poultry who has a Bio Safety Level ...
... West Java province, poultry depopulation is being conducted by culling ... of// avian flu in this area. ,According to ... Rachmat said that this plan of mass culling was made ... tested positive for bird flu. ,According to Andi, ...
Cached Medicine News:Health News:Gene linked to Hearing Loss in Aged Identified 2Health News:Major Hurdle towards Development of Bird Flu Vaccine in India. 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: